Fulvestrant vs exemestane for treatment of metastatic breast cancer in patients with acquired resistance to non-steroidal aromatase inhibitors -- a meta-analysis of EFECT and SoFEA (CRUKE/03/021 & CRUK/09/007).

Saved in:
Bibliographic Details
Title: Fulvestrant vs exemestane for treatment of metastatic breast cancer in patients with acquired resistance to non-steroidal aromatase inhibitors -- a meta-analysis of EFECT and SoFEA (CRUKE/03/021 & CRUK/09/007).
Authors: Johnston, S. R. D., Chia, S., Kilburn, L. S., Gradishar, W. J., Cameron, D., Dodwell, D., Ellis, P., Howell, A., Im, Y.-H., Coombes, G., Piccart, M., Dowsett, M., Bliss, J.
Source: Cancer Research. Dec2012 Meeting Abstracts, Vol. 72 Issue 24a, p753-754. 2p.
Database: Academic Search Ultimate
Description
ISSN:00085472
DOI:10.1158/0008-5472.SABCS12-P2-14-01